The simplified registration route for herbal medicines changed its documentary basis in 2026, but “simplified” does not mean “without evidence,” nor does it justify concluding that any product made from the same plant works for any purpose. The new framework, approved by Brazil’s health regulator Anvisa in December 2025 and implemented in February 2026, reorganized registration and notification rules, updated quality-control requirements for plant extracts, and introduced a more detailed structure of monographs, assessment reports, and opinions for the abbreviated pathway.
The key to understanding the change is to separate three questions: does the product meet quality requirements?, does the regulatory pathway accept a particular basis for safety and efficacy or effectiveness?, and what exactly has been demonstrated for that ingredient, preparation, dose, and indication? Registration answers a defined set of regulatory conditions; it does not turn the plant into generic proof of clinical efficacy.
What entered into force under the new framework
The package approved in December 2025 includes RDC 1,004/2025, which governs registration of herbal medicines and registration or notification of traditional herbal medicines, as well as INs 410, 411, and 412/2025. IN 410 covers prohibitions and restrictions on composition; IN 411 governs pesticide-residue control; and IN 412 establishes the Brazilian list of plant species that can support simplified registration when the standardized requirements are followed in full.
In February 2026, Anvisa published the new simplified-registration documentation package: seven monographs, seven assessment reports, and four non-inclusion opinions. According to the Agency, these documents replace material that had previously been concentrated in IN 2/2014 and provide standardized information for each plant active ingredient accepted through this route. The monographs summarize regulatory conditions; the assessment reports describe the scientific and technical literature reviewed; and the non-inclusion opinions explain why certain species were not added. See Anvisa’s publication on the 2026 documents and the official simplified-registration page.
How simplified registration works
RDC 1,004/2025 defines simplified registration as an abbreviated registration pathway. The pathway is abbreviated because Anvisa has already standardized, in Brazilian monographs or recognized monographs from the European Medicines Agency’s Committee on Herbal Medicinal Products (HMPC/EMA), a set of conditions that an applicant may rely on.
This only applies when the proposed product fits the relevant parameters in full. The RDC itself requires that, when safety and efficacy or effectiveness are demonstrated through simplified registration, the applicant must follow all standardized information. Therefore, using a plant species with the same name is not enough: the herbal active pharmaceutical ingredient, preparation, quality, specifications, indication, dosage, and other conditions stated in the monograph matter.
What changed, what did not, and what cannot be inferred
| What changed | What did not change | What registration alone does not establish |
|---|---|---|
| The framework now addresses the specific characteristics of plant extracts and different levels of knowledge about their active constituents more directly. | Herbal medicines remain subject to quality requirements, raw-material controls, good practices, and safety assessment. | That any presentation, tea, supplement, or homemade preparation from the same plant is equivalent to the registered medicine. |
| Simplified registration now has more detailed and standardized monographs, assessment reports, and non-inclusion opinions. | The abbreviated route depends on compliance with the established regulatory conditions; it does not eliminate the quality dossier or the manufacturer’s obligations. | That the plant is effective for every traditional claim, at any dose, or in any population. |
| The new rules better distinguish situations in which therapeutic constituents are known from those in which the effect is attributed to the broader phytocomplex, adapting quality control to the extract type. | The assessment remains tied to the product, the active plant ingredient, and the proposed conditions of use. | That a registered product is superior to another treatment or automatically replaces professional care. |
| Specific rules also address composition restrictions and pesticide-residue control. | “Natural” is not a regulatory synonym for “risk-free.” | That the absence of a specific restriction proves additional clinical benefit. |
Herbal medicines and traditional herbal medicines are not the same category
The distinction matters because the accepted evidence base is not identical. Under RDC 1,004/2025, a herbal medicine is defined as one whose safety and efficacy are supported by clinical evidence and whose quality must remain consistent. For this category, safety and efficacy may be demonstrated through nonclinical and clinical trials or, where applicable, through simplified registration based on Brazilian monographs or HMPC/EMA well-established use monographs.
A traditional herbal medicine, by contrast, has safety and effectiveness supported by scientific and technical data and is developed for conditions compatible with use without the need for diagnosis, prescription, and medical follow-up. The RDC allows, among the options, evidence of safe and effective traditional use for at least 30 years or simplified registration based on a Brazilian monograph or an HMPC/EMA traditional-use monograph. The rule also limits this category: it must not be intended to treat diseases, disorders, or conditions considered serious.
This distinction helps prevent a common misreading: traditional use and clinical efficacy are not interchangeable expressions. The framework recognizes different regulatory categories and requires communication to users to preserve that distinction.
Simplified registration does not mean Anvisa “waived evidence”
Under the new model, part of the assessment can rely on knowledge already consolidated in monographs instead of requiring every company to repeat from scratch the full demonstration for a condition that has already been standardized. Even so, the RDC requires safety and efficacy or effectiveness documentation to be relevant to the specific medicine or active plant ingredient, requires a benefit-risk discussion, and requires consideration of available favorable and unfavorable information.
The 2026 monograph package reinforces that logic. Anvisa stated that the documents were built from a review of scientific and technical literature, with participation by CNPq-contracted researchers, review by industry associations and the Agency, public consultation, and approval by Anvisa’s Collegiate Board. That is very different from saying that every plant-based product receives an automatic presumption of benefit.
What registration does not prove by itself
- It does not prove that “the plant works” for every purpose. The regulatory conclusion is tied to a preparation, an active plant ingredient, an indication, and defined conditions of use.
- It does not make different products using the same species equivalent. Extract type, manufacturing process, markers, concentration, purity, and quality control can materially change the product.
- It does not prove superiority. Obtaining registration does not mean the product has been shown to be better than another medicine, intervention, or therapeutic option unless that comparison is part of the evidence submitted.
- It does not turn traditional use into a clinical trial. For traditional herbal medicines, the regulation itself recognizes an effectiveness basis distinct from that required for herbal medicines supported by clinical efficacy.
- It does not eliminate risks, contraindications, or interactions. Regulatory authorization includes risk assessment and communication, but no registration means zero risk.
- It does not automatically validate claims outside the approved labeling or regulatory scope. Extrapolations to different doses, populations, combinations, or uses need their own evidentiary basis.
Simplified registration and notification are not synonyms either
RDC 1,004/2025 maintains a notification route for certain traditional herbal medicines that meet conditions in the Brazilian Pharmacopoeia’s Herbal Medicines Formulary and other requirements. Simplified registration, meanwhile, remains registration — only through an abbreviated route based on previously established standards. Mixing the two concepts can create the false impression that every “simplified” product is merely reported to Anvisa without the corresponding regulatory framework.
How to interpret a regulated herbal medicine without overreaching
- Identify whether the product is classified as a herbal medicine or a traditional herbal medicine.
- Check the approved indication, directions, dose, contraindications, and warnings instead of relying only on the plant’s common name.
- Keep in mind that the regulatory evidence follows the product and the standardized active plant ingredient, not any homemade preparation or product in another commercial category.
- When discussing clinical efficacy, distinguish clinical trials, well-established use, traditional use, and inferences drawn from indirect literature.
- To follow implementation of the new framework, consult Anvisa’s primary sources, including its explanation of the framework’s approval and the August 2026 seminar recap, which highlighted changes in quality control, safety and efficacy, labeling, and package information.
The central gain of the 2026 framework is to make the regulatory pathway more coherent with the characteristics of plant-derived medicines and to reuse previously assessed evidence when standardized conditions are met. The correct interpretation, however, remains specific: registration is evidence that a product was authorized under defined criteria; it is not permission to generalize efficacy to an entire plant, every use, or every presentation.
